Baseline Body Surface Area and Itch Severity Define Response to Baricitinib in Patients with Moderate-to-Severe Atopic Dermatitis at Week 16-Reference-Cited by-同舟云学术

Baseline Body Surface Area and Itch Severity Define Response to Baricitinib in Patients with Moderate-to-Severe Atopic Dermatitis at Week 16

Published:2023-06-19 Issue:8 Volume:40 Page:3574-3587
ISSN:0741-238X
Container-title:Advances in Therapy
language:en
Short-container-title:Adv Ther

Author:

Thyssen Jacob P.,de Bruin-Weller Marjolein,Costanzo Antonio,Grond Susanne,Schuster Christopher,Liu Chunyuan,Rueda Maria Jose,Chen Yun-Fei,Pinter Andreas,Bieber Thomas

Funder

Eli Lilly and Company

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s12325-023-02528-8.pdf

Reference25 articles.

1. Bieber T, et al. Clinical phenotypes and endophenotypes of atopic dermatitis: Where are we, and where should we go? J Allergy Clin Immunol. 2017;139(4s):S58-s64.

2. Renert-Yuval Y, et al. Biomarkers in atopic dermatitis-a review on behalf of the International Eczema Council. J Allergy Clin Immunol. 2021;147(4):1174-1190.e1.

3. Kantor R, et al. Research letter: impact of pruritus on quality of life—a systematic review. J Am Acad Dermatol. 2016;75(5):885-886.e4.

4. Chovatiya R, et al. Clinical phenotyping of atopic dermatitis using combined itch and lesional severity: a prospective observational study. Ann Allergy Asthma Immunol. 2021;127(1):83-90.e2.

5. Olumiant. European Union Summary of Product Characteristics. Eli Lilly and Company. 2021 [cited 2023 10 February]; https://www.ema.europa.eu/en/documents/product-information/olumiant-epar-productinformation_en.pdf. Accessed 10 Feb 2023.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Attentiveness and mental health in adolescents with moderate-to-severe atopic dermatitis without ADHD;Archives of Dermatological Research;2024-07-30

2. Cambiando el enfoque en el tratamiento de la dermatitis atópica: inhibidores de la JAK, un nuevo panorama;Revista de la Asociación Colombiana de Dermatología y Cirugía Dermatológica;2024-07-30

3. Baricitinib Improvement Across Regions in Atopic Dermatitis Patients with Baseline Body Surface Area up to 40% and Severe Itch;Dermatology and Therapy;2024-05-22

4. Management of Patients Affected by Moderate-to-Severe Atopic Dermatitis with JAK Inhibitors in Real-World Clinical Practice: An Italian Delphi Consensus;Dermatology and Therapy;2024-03-21

5. Real‐world effectiveness and safety of abrocitinib in 12 Japanese patients with atopic dermatitis and transcriptome analysis with peripheral blood;The Journal of Dermatology;2024-03-03